Protocol Title: A Phase 2, Randomized, Parallel, Open-Label Study to investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

Sponsor: GSK

Protocol Number: 209628 “DREAMM14”

Key Criteria

  • Relapsed or Refractory Multiple Myeloma
    • Has undergone stem cell transplant or is considered transplant ineligible 

AND

  • Has failed at least 3 prior lines of therapy, including an anti-CD38 antibody (e.g. lenalidomide, pomalidomide) and is refractory to an immunomodulatory agent (e.g. lenalidomide, pomalidomide) and a proteasome inhibitor (e.g. bortexomib, ixazomib, carfilzomib)

Talking Points

Scroll to Top